Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01168882 Org: User:
Start: 11/30/11 End: 07/31/15 Due: 07/31/16

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00707304 Org: User:
Start: 11/30/08 End: 08/31/12 Due: 08/31/13

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Phase: N/A Priority: Normal
NCT ID: NCT00630656 Org: User:
Start: 04/30/08 End: 02/28/10 Due: 02/28/11

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Phase: N/A Priority: Normal
NCT ID: NCT00854633 Org: User:
Start: 06/30/09 End: 12/31/12 Due: 12/31/13

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Phase: N/A Priority: Normal
NCT ID: NCT00450970 Org: User:
Start: 02/28/07 End: 12/31/09 Due: 12/31/10

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00093132 Org: User:
Start: 08/31/04 End: 02/28/09 Due: 02/28/10

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00268970 Org: User:
Start: 12/31/05 End: 09/30/09 Due: 09/30/10

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00329329 Org: User:
Start: 05/31/06 End: 02/28/09 Due: 02/28/10

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Phase: N/A Priority: Normal
NCT ID: NCT00265655 Org: User:
Start: 11/30/05 End: 02/29/08 Due: 02/28/09

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00706862 Org: User:
Start: 02/28/09 End: 03/31/16 Due: 03/31/17

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Phase: N/A Priority: Normal
NCT ID: NCT01273779 Org: User:
Start: 06/30/11 End: 12/31/14 Due: 12/31/15

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT00480623 Org: User:
Start: 05/31/07 End: 04/30/08 Due: 04/30/09

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT00313456 Org: User:
Start: 03/31/06 End: 03/31/09 Due: 03/31/10

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Phase: N/A Priority: Normal
NCT ID: NCT00069745 Org: User:
Start: 09/30/03 End: 03/31/07 Due: 03/31/08

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00095186 Org: User:
Start: 09/30/04 End: 03/31/07 Due: 03/31/08

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT00125411 Org: User:
Start: 03/31/07 End: 02/28/09 Due: 02/28/10

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00370383 Org: User:
Start: 07/31/06 End: 03/31/09 Due: 03/31/10